Systemic Lupus Erthematosus
18
9
9
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (18)
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Patient-Centered Assessment of Symptoms and Outcomes
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
A Study of GR1803 in Systemic Lupus Erythematosus
Water-based Liuzijue Exercise on Childhood-onset Systemic Lupus Erythematosus
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Cardiovascular Risk in Children With Chronic Conditions Study
Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
Fatigue in Systemic Lupus Erythematosus
Rare AutoImmune SElf-management Programme Development
Bone Mineral Density in Patients with Childhood-onset Systemic Lupus Erythematous, in Relation to Disease Clinical Criteria
Omalizumab for Lupus